首页 › 急性髓系白血病 › 加利福尼亚州 › Mountain View
Mountain View CA 急性髓系白血病临床试验
19项针对 急性髓系白血病的研究正在 Mountain View及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
招募中1 期
- Lucile Packard Children's Hospital /ID# 276015, Palo Alto · 距离 5 英里
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
招募中1 期
- Stanford Health Care, Stanford · 距离 5 英里
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 距离 5 英里
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
招募中2 期
- Stanford Cancer Institute, Stanford · 距离 5 英里
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Lucile Packard Children's Hospital Stanford University, Palo Alto · 距离 5 英里
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
招募中1 期
- Lucille Packard Children's Hospital of Stanford University, Palo Alto · 距离 5 英里
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
招募中1 期
- Stanford University, Palo Alto · 距离 5 英里
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
招募中1 期
- Stanford University, Palo Alto · 距离 5 英里
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中观察性研究
- Stanford University Medical Center, Stanford · 距离 5 英里
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
招募中1 期
- Stanford University, Palo Alto · 距离 5 英里
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
招募中1 期
- Stanford University, Stanford · 距离 5 英里
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
招募中1/2 期
- Stanford University, Palo Alto · 距离 5 英里
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Stanford University, Palo Alto · 距离 5 英里
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- Stanford, Palo Alto · 距离 5 英里
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
招募中1 期
- Stanford Medical Center, Palo Alto · 距离 5 英里
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
招募中1 期
- Stanford University, Stanford · 距离 5 英里
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
招募中1 期
- Stanford Cancer Center, Palo Alto · 距离 5 英里
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
招募中1/2 期
- Stanford Cancer Center, Palo Alto · 距离 5 英里
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
招募中欢迎健康志愿者
- Stanford University, Stanford · 距离 5 英里
其他城市的 急性髓系白血病试验
- Houston, TX85 项研究
- New York City, NY51 项研究
- Boston, MA44 项研究
- Seattle, WA41 项研究
- Baldwin Park, CA40 项研究
- Columbus, OH35 项研究
- Philadelphia, PA34 项研究
- Durham, NC33 项研究
- Atlanta, GA31 项研究
- Tampa, FL29 项研究
- Chicago, IL26 项研究
- Portland, OR25 项研究
Mountain View的其他研究
- 癌症（所有类型）40 项研究
- 乳腺癌26 项研究
- 转移性癌症25 项研究
- 非小细胞肺癌21 项研究
- 卵巢癌19 项研究
- 自闭症谱系障碍17 项研究
- 肺癌17 项研究
- 前列腺癌15 项研究
- 心力衰竭15 项研究
- 自闭症13 项研究
- 急性淋巴细胞白血病13 项研究
- 结直肠癌13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。